Funding for this research was provided by:
Novartis Pharmaceuticals Corporation (HEORUSV201137)
National Center for Advancing Translational Sciences (TL1 - UL1TR000161)
Received: 30 April 2020
Accepted: 21 September 2020
First Online: 29 September 2020
Ethics approval and consent to participate
: The study was approved by the University of Massachusetts Medical School Institutional Review Board. All participants provided written informed consent.
: Not applicable.
: Dr. Lapane has served as a consultant to Barbara Zorowitz periodically to review prescribing guideline in post-acute settings for Empirian. Dr. Kay has served as a consultant to pharmaceutical companies. Dr. Yi is an employee of Novartis.